The effects of caffeine mouth rinsing on selective attention as a function of different caffeine concentrations and perceived taste intensity in recreationally active males at rest: a randomized placebo-controlled cross-over trial.

IF 3.5 3区 医学 Q2 NEUROSCIENCES
Cemile Balcı, Neşe Toktaş, Kemal Alparslan Erman, Abdurrahman Aktop, Ethem Kavukçu, Asuman Şahan
{"title":"The effects of caffeine mouth rinsing on selective attention as a function of different caffeine concentrations and perceived taste intensity in recreationally active males at rest: a randomized placebo-controlled cross-over trial.","authors":"Cemile Balcı, Neşe Toktaş, Kemal Alparslan Erman, Abdurrahman Aktop, Ethem Kavukçu, Asuman Şahan","doi":"10.1007/s00213-024-06710-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>The effect of caffeine mouth rinsing (CAF-MR) on cognitive performance has not been thoroughly investigated.</p><p><strong>Objectives: </strong>To evaluate the effects of different concentrations of CAF-MR on selective attention in relation to perceived taste intensity.</p><p><strong>Methods: </strong>A total of 30 healthy and recreationally active male subjects were included in this randomized, double-blind, placebo-controlled crossover trial. Interventions included MR for 20 s at rest with three different caffeine solutions (0.24% [60 mg/25 mL], 0.6% [150 mg/25 mL], and 1.2% [300 mg/25 mL]), MR with 25 mL water (placebo), and no MR (control). Data on Victoria Stroop Test (VST) and the perceived taste intensity were recorded at five sessions.</p><p><strong>Results: </strong>CAF-MR-300 mg intervention significantly decreased completion time (from 62.93 ± 19.07 to 57.01 ± 16.74 s, p = 0.002 in Part D), while CAF-MR-150 mg intervention significantly decreased number of errors in Part D (7.00 ± 6.21 vs. 5.63 ± 5.76, p = 0.04) and Part C (8.77 ± 8.80 vs. 7.10 ± 7.11, p = 0.02). Perceived difficulty was significantly decreased both after CAF-MR with 150 mg (5.57 ± 1.65 vs. 4.77 ± 1.98, p = 0.006) and 300 mg (5.95 ± 1.77vs. 4.67 ± 1.96, p < 0.001). Perceived taste intensity for 300 mg of caffeine was negatively correlated with completion time (r: ranged, 0.37 to 0.46, p ranged, 0.045 to 0.009) after 300 mg, 150 mg (p ranged, 0.04 to 0.005) and placebo (p ranged 0.044 to 0.03) interventions.</p><p><strong>Conclusions: </strong>This study is the first to demonstrate that CAF-MR shows dose-dependent effects on selective attention in healthy recreational males, such as improved speed (for 300 mg caffeine), reduced error rate (for 150 mg caffeine) and decrease in perceived difficulty (for 150 and 300 mg caffeine).</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-024-06710-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: The effect of caffeine mouth rinsing (CAF-MR) on cognitive performance has not been thoroughly investigated.

Objectives: To evaluate the effects of different concentrations of CAF-MR on selective attention in relation to perceived taste intensity.

Methods: A total of 30 healthy and recreationally active male subjects were included in this randomized, double-blind, placebo-controlled crossover trial. Interventions included MR for 20 s at rest with three different caffeine solutions (0.24% [60 mg/25 mL], 0.6% [150 mg/25 mL], and 1.2% [300 mg/25 mL]), MR with 25 mL water (placebo), and no MR (control). Data on Victoria Stroop Test (VST) and the perceived taste intensity were recorded at five sessions.

Results: CAF-MR-300 mg intervention significantly decreased completion time (from 62.93 ± 19.07 to 57.01 ± 16.74 s, p = 0.002 in Part D), while CAF-MR-150 mg intervention significantly decreased number of errors in Part D (7.00 ± 6.21 vs. 5.63 ± 5.76, p = 0.04) and Part C (8.77 ± 8.80 vs. 7.10 ± 7.11, p = 0.02). Perceived difficulty was significantly decreased both after CAF-MR with 150 mg (5.57 ± 1.65 vs. 4.77 ± 1.98, p = 0.006) and 300 mg (5.95 ± 1.77vs. 4.67 ± 1.96, p < 0.001). Perceived taste intensity for 300 mg of caffeine was negatively correlated with completion time (r: ranged, 0.37 to 0.46, p ranged, 0.045 to 0.009) after 300 mg, 150 mg (p ranged, 0.04 to 0.005) and placebo (p ranged 0.044 to 0.03) interventions.

Conclusions: This study is the first to demonstrate that CAF-MR shows dose-dependent effects on selective attention in healthy recreational males, such as improved speed (for 300 mg caffeine), reduced error rate (for 150 mg caffeine) and decrease in perceived difficulty (for 150 and 300 mg caffeine).

咖啡因漱口对选择性注意力的影响是不同咖啡因浓度和感知味觉强度在娱乐活动男性休息时的作用:一项随机安慰剂对照交叉试验。
理由:咖啡因漱口水(CAF-MR)对认知能力的影响尚未得到深入研究:评估不同浓度的咖啡因漱口水对选择性注意力的影响,以及与感知味觉强度的关系:这项随机、双盲、安慰剂对照交叉试验共纳入了 30 名健康的娱乐活动男性受试者。干预措施包括在静止状态下用三种不同的咖啡因溶液(0.24% [60 毫克/25 毫升]、0.6% [150 毫克/25 毫升] 和 1.2% [300 毫克/25毫升])进行 20 秒钟的磁共振,用 25 毫升水(安慰剂)进行磁共振,以及不进行磁共振(对照组)。在五个疗程中记录了维多利亚-斯特罗普测试(VST)数据和感知味觉强度:CAF-MR-300 毫克的干预明显减少了完成时间(D 部分从 62.93 ± 19.07 秒减少到 57.01 ± 16.74 秒,p = 0.002),而 CAF-MR-150 毫克的干预明显减少了 D 部分(7.00 ± 6.21 vs. 5.63 ± 5.76,p = 0.04)和 C 部分(8.77 ± 8.80 vs. 7.10 ± 7.11,p = 0.02)的错误次数。使用 150 毫克(5.57±1.65 vs. 4.77±1.98,p = 0.006)和 300 毫克(5.95±1.77vs. 4.67±1.96,p 结论:CAF-MR 后,感知难度均明显降低:这项研究首次证明,CAF-MR 对健康休闲男性的选择性注意力有剂量依赖性影响,如提高速度(300 毫克咖啡因)、降低错误率(150 毫克咖啡因)和降低感知难度(150 毫克和 300 毫克咖啡因)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychopharmacology
Psychopharmacology 医学-精神病学
CiteScore
7.10
自引率
5.90%
发文量
257
审稿时长
2-4 weeks
期刊介绍: Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信